Latest Videos |view all videos
Rory L. Smoot, M.D., describes treatment options and the specialized team of experts at Mayo Clinic who provide care for patients with cholangiocarcinoma.
R. Jeffrey Karnes, M.D., consultant and associate professor, Mayo Clinic, discusses treatment options for bladder cancer. The ailment can be subdivided into subcategories, and the treatments dramatically differ. Invasive treatments can ...
Jon Ebbert, M.D., of the Mayo Clinic Nicotine Dependence Center, on a study combining the smoking cessation medications varenicline and bupropion, compared with varenicline alone, that resulted in higher smoking abstinence rates.
Richard D. Hurt, M.D., director of Mayo Clinic's Nicotine Dependence Center, comments on a new report by the Surgeon General released Jan. 2014, The Health Consequences of Smoking — 50 Years of Progress, which highlights a half-century ...
Amplification of HER2, a known driver of some breast cancers, in a type of bladder cancer called micropapillary urothelial carcinoma (MPUC), has shown that the presence of HER2 amplification is associated with particularly aggressive tumors.
Alan P. Fields, Ph.D., and Dr. Monica Flynn Jacoby, professor of cancer studies at Mayo Clinic's campus in Florida, talk about the publication of his team's latest discovery.
Judy C. Boughey, M.D., and Matthew P. Goetz, M.D., present Breast Cancer Genome-Guided Therapy Study: Next-Generation Sequencing for the Management of Women With High-Risk Breast Cancer.
A study published today in the journal BMJ says annual screening mammograms in women ages 40 to 59 do not reduce deaths from breast cancer any better than a physical examination or usual care.
Panagiotis Z. Anastasiadis, Ph.D., presents Targeting Polarity Pathways for Cancer Treatment.
Newly diagnosed patients with diffuse large B cell lymphoma (DLBCL) who do not experience any cancer-related outcome events for two years after diagnosis have essentially the same life expectancy as they did prior to diagnosis, a Mayo ...
Blacks may be twice as likely as whites to develop multiple myeloma because they are also more likely to have a precursor condition known as monoclonal gammopathy of undetermined significance.
With the glut of data generated through next-generation sequencing, interpretation has become the new bottleneck in scientific discovery and clinical application.